SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 192.74-0.2%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (25870)9/29/1998 7:52:00 PM
From: Arthur Radley  Read Replies (4) of 32384
 
Henry and others:
With this buy-out clause with Elan, does it not bother anyone that here LNGD has had an ongoing working relationship with many of the major drug companies and NOW they strike such a deal with a totally new entity. In this deal they take on another penny-ante drug. What will make or break LGND IMO is Targretin. My question is why wouldn't one of these original companies working with LGND and with LGND's discoveries, and having inside information on LGND's potential, why would not one of them strike this deal with LGND. IMO it wasn't the Elan compound that was integral to this deal. Is LGND's mode of operation always to look for the next "fool" to keep them going?
Just wondering, because the market apparently didn't like this further dilution and you can add me to that crowd.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext